

# **C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/CA59AD6DAD3AEN.html>

Date: September 2022

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: CA59AD6DAD3AEN

## **Abstracts**

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Drugs In Development, 2022, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Immunology, Central Nervous System,

Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders, Oncology and Respiratory which include indications Autoimmune Disorders, Alzheimer's Disease, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Huntington Disease, Parkinson's Disease, Allergic Asthma, Amyotrophic Lateral Sclerosis, Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Bullous Pemphigoid, Chronic Inflammation, Churg-Strauss Syndrome, Glomerulonephritis, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Inflammatory Pain, Kidney Disease (Nephropathy), Lupus Nephritis, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Neutropenia, Pain, Periodontitis, Peritonitis, Solid Tumor and Transplant Rejection.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)

The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects

The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones

Featured News & Press Releases

Aug 24, 2022: ChemoCentryx announces TAVNEOS (avacopan) presentations at upcoming medical conferences

Aug 18, 2022: UK NICE recommends Vifor's Tavneos for AAV treatment

May 31, 2022: Chemocentryx announces abstracts of TAVNEOS to be presented at June rheumatology, oncology and nephrology conferences

May 18, 2022: ChemoCentryx announces presentation at the society for investigative dermatology meeting highlighting the role of tunnels in driving ongoing disease in hidradenitis suppurativa

May 11, 2022: ChemoCentryx announces upcoming conference abstracts focused on TAVNEOS (avacopan) and the burden of systemic glucocorticoid use in ANCA-associated vasculitis

Apr 21, 2022: Health Canada approves Vertex's Trikafta for cystic fibrosis in children

Jan 19, 2022: ChemoCentryx announces EU approval of TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis

Jan 10, 2022: InflaRx announces new pipeline program - oral C5aR inhibitor  
Nov 12, 2021: VFMCRP receives positive CHMP opinion for Tavneos for the treatment of ANCA-associated vasculitis  
Nov 04, 2021: Abstracts at the annual meetings of the American Society of Nephrology and American College of Rheumatology highlight potential value of TAVNEOS (avacopan)  
Oct 14, 2021: PANTHERx Rare Pharmacy selected by ChemoCentryx to distribute TAVNEOS (avacopan) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis  
Oct 13, 2021: Amber Specialty Pharmacy selected by ChemoCentryx to dispense TAVNEOS (avacopan), an adjunctive treatment for ANCA-associated vasculitis  
Oct 08, 2021: ChemoCentryx announces FDA approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis  
Sep 27, 2021: VFMCRP announces approval for TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis in Japan  
Jul 06, 2021: Innate Pharma to stop development of avdoralimab for Covid-19

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Indications, 2022 (Contd..1)  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by Alsonex Pty Ltd, 2022  
Pipeline by ChemoCentryx Inc, 2022  
Pipeline by Dompe Farmaceutici SpA, 2022  
Pipeline by InflaRx NV, 2022  
Pipeline by Innate Pharma SA, 2022  
Pipeline by MorphoSys AG, 2022  
Pipeline by Prommune Inc, 2022  
Pipeline by Teva Pharmaceutical Industries Ltd, 2022  
Pipeline by Visterra Inc, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CA59AD6DAD3AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA59AD6DAD3AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

